{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:34:09Z","timestamp":1794562449740,"version":"4.9.1"},"reference-count":26,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial aims to establish whether initial treatment with selective laser trabeculoplasty (SLT) is superior to initial treatment with topical medication for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>The LiGHT Trial is a prospective, unmasked, multicentre, pragmatic, randomised controlled trial. 718 previously untreated patients with POAG or OHT were recruited at six collaborating centres in the UK between 2012 and 2014. The trial comprises two treatment arms: initial SLT followed by conventional medical therapy as required, and medical therapy without laser therapy. Randomisation was provided online by a web-based randomisation service. Participants will be monitored for 3 years, according to routine clinical practice. The target intraocular pressure (IOP) was set at baseline according to an algorithm, based on disease severity and lifetime risk of loss of vision at recruitment, and subsequently adjusted on the basis of IOP control, optic disc and visual field. The primary outcome measure is health-related quality of life (HRQL) (EQ-5D five-level). Secondary outcomes are treatment pathway cost and cost-effectiveness, Glaucoma Utility Index, Glaucoma Symptom Scale, Glaucoma Quality of Life, objective measures of pathway effectiveness, visual function and safety profiles and concordance. A single main analysis will be performed at the end of the trial on an intention-to-treat basis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The LiGHT Trial is a multicentre, pragmatic, randomised clinical trial that will provide valuable data on the relative HRQL, clinical effectiveness and cost-effectiveness of SLT and topical IOP-lowering medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ISRCTN32038223, Pre-results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-310877","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T21:11:28Z","timestamp":1505337088000},"page":"593-598","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":79,"title":["Laser in Glaucoma and Ocular Hypertension (LiGHT) trial. A multicentre, randomised controlled trial: design and methodology"],"prefix":"10.1136","volume":"102","clinical-trial-number":[{"clinical-trial-number":"isrctn32038223","registry":"10.18810\/isrctn"}],"author":[{"given":"Gus","family":"Gazzard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Konstantakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garway-Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wormald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Buszewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Ambler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0935-3713","authenticated-orcid":false,"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,9,13]]},"reference":[{"key":"2020050713011094000_102.5.593.1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.081224"},{"key":"2020050713011094000_102.5.593.2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0886"},{"key":"2020050713011094000_102.5.593.3","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200304000-00009"},{"key":"2020050713011094000_102.5.593.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62111-5"},{"key":"2020050713011094000_102.5.593.5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ophtha.2007.03.088","article-title":"Glaucoma and mortality","volume":"115","author":"Sharkawi","year":"2008","journal-title":"Ophthalmology"},{"key":"2020050713011094000_102.5.593.6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/OPTH.S9716","article-title":"Incidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications","volume":"4","author":"Fukuchi","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"2020050713011094000_102.5.593.7","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200106000-00017"},{"key":"2020050713011094000_102.5.593.8","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802379996"},{"key":"2020050713011094000_102.5.593.9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ajo.2016.05.001","article-title":"Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma","volume":"168","author":"Schultz","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"2020050713011094000_102.5.593.10","doi-asserted-by":"crossref","unstructured":"Rolim de Moura C , Paranhos A , Wormald R . Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev 2007:CD003919.doi:10.1002\/14651858.CD003919.pub2","DOI":"10.1002\/14651858.CD003919.pub2"},{"key":"2020050713011094000_102.5.593.11","unstructured":"National Institute for Health and Clinical Excellence. NICE: Guidance on Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension: DoH. 2010 www.nice.org.uk\/CG85fullguideline."},{"key":"2020050713011094000_102.5.593.12","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2020050713011094000_102.5.593.13","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0b013e3181339f30"},{"key":"2020050713011094000_102.5.593.14","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.116.7.861"},{"key":"2020050713011094000_102.5.593.15","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmi027"},{"key":"2020050713011094000_102.5.593.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-4182(03)80060-1"},{"key":"2020050713011094000_102.5.593.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.07.044"},{"key":"2020050713011094000_102.5.593.18","unstructured":"Society EG. Terminology and Guidelines for Glaucoma. 3rd edition, 2008. Available from. http:\/\/www.eugs.org\/eng\/EGS_guidelines.asp."},{"key":"2020050713011094000_102.5.593.19","unstructured":"Office of Health Economics. OHE Seminar Launches \u2018An EQ-5D-5L Value Set for England\u2019 - See more at. 2014 https:\/\/www.ohe.org\/news\/ohe-seminar-launches-eq-5d-5l-value-set-england#sthash.cwJwmGYP.dpuf."},{"key":"2020050713011094000_102.5.593.20","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.ophtha.2013.01.002","article-title":"Development and validation of a predictive model for nonadherence with once-daily glaucoma medications","volume":"120","author":"Chang","year":"2013","journal-title":"Ophthalmology"},{"key":"2020050713011094000_102.5.593.21","doi-asserted-by":"crossref","unstructured":"Azuara-Blanco A , Burr JM , Cochran C , et al . The effectiveness of early lens extraction with intraocular lens implantation for the treatment of primary angle-closure glaucoma (EAGLE): study protocol for a randomized controlled trial. Trials 2011;12:133.doi:10.1186\/1745-6215-12-133","DOI":"10.1186\/1745-6215-12-133"},{"key":"2020050713011094000_102.5.593.22","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0559"},{"key":"2020050713011094000_102.5.593.23","doi-asserted-by":"crossref","unstructured":"Vickerstaff V , Ambler G , Bunce C , et al . Statistical analysis plan for the Laser-1st versus Drops-1st for Glaucoma and Ocular Hypertension Trial (LiGHT): a multi-centre randomised controlled trial. Trials 2015;16:517.doi:10.1186\/s13063-015-1047-9","DOI":"10.1186\/s13063-015-1047-9"},{"key":"2020050713011094000_102.5.593.24","unstructured":"The james lind alliance. Priorities for glaucoma research. 2015 http:\/\/www.lindalliance.org\/top-tens.asp."},{"key":"2020050713011094000_102.5.593.25","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.052795"},{"key":"2020050713011094000_102.5.593.26","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e318218287f"}],"updated-by":[{"DOI":"10.1136\/bjophthalmol-2017-310877corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000}}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-310877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T04:55:55Z","timestamp":1601096155000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-310877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,13]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,19]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/bjophthalmol-2017-310877"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310877","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310877.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310877.supp2","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310877.supp3","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310877.supp4","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-310877.supp5","asserted-by":"subject"}]},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,13]]}}}